Oncternal Therapeutics Inc Stock

$0.53

0.00%

Nasdaq, Mon, Jul 07 2025

ISIN

US68236P1075

Symbol

ONCT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Oncternal Therapeutics Inc Stock price

$0.53

-51.27 98.98% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

+0.00 0.00%

ISIN

US68236P1075

Symbol

ONCT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$1.6m

Enterprise Value

$-13.0m

Net debt

positive

Cash

$14.6m

Shares outstanding

3.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.7 | 0.8

EV/Sales

negative | negative

EV/FCF

0.5

P/B

0.2

Financial Health

Equity Ratio

81.8%

Return on Equity

-131.4%

ROCE

-393.0%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$2.2m | $1.9m

EBITDA

- | -

EBIT

$-36.0m | -

Net Income

$-34.6m | $-36.8m

Free Cash Flow

$-26.6m

Growth (TTM | estimate)

Revenue

227.3% | 143.0%

EBITDA

- | -

EBIT

18.3% | -

Net Income

17.1% | 6.8%

Free Cash Flow

23.4%

EPS

$-11.7

FCF per Share

$-9.0

Short interest

0.5%

Employees

Rev per Employee

$30.0k

As a Free StocksGuide user, you can view scores for all 6,973 stocks worldwide.

Get Started for Free Today

Oncternal Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Oncternal Therapeutics Inc forecast:

3x Hold

50%

3x Sell

50%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Oncternal Therapeutics Inc forecast:

Hold

50%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from Oncternal Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	2.16 2.16	227% 227% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	12 12	3% 3% 571%
- Research and Development Expense	26 26	19% 19% 1,194%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-36 -36	18% 18% -1,665%
Net Profit	-35 -35	17% 17% -1,601%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Oncternal Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

7 days ago

Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T...

Neutral

GlobeNewsWire

●

4 months ago

Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC

SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission on March 17, 2025, which will remove Oncternal's securities from listing and registration on Nasdaq, and to subsequently deregister with the Securities and Exchange Commissi...

https://seekingalpha.com/article/4691590-oncternal-therapeutics-inc-onct-q1-2024-earnings-call-transcript

More Oncternal Therapeutics Inc News

Company Profile

Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focuses on drug development of untapped biological pathways implicated in cancer progression. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.

Head office	United States
CEO	James Breitmeyer
Employees	29
Founded	1997
Website	www.oncternal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now